26581 Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB108
Author(s):  
Antonio Costanzo ◽  
Curdin Conrad ◽  
Talia Gramiccia ◽  
Maria Jazra ◽  
Elke M.G. J. de Jong ◽  
...  
Keyword(s):  
Severe Psoriasis ◽  
Post Hoc Analysis ◽  
Post Hoc

25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB70
Author(s):  
Kristian Reich ◽  
Joseph F. Merola ◽  
Boni Elewski ◽  
Kim A. Papp ◽  
Luis Puig ◽  
...  
Keyword(s):  
Severe Psoriasis ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study

2018 ◽  
Vol 2 ◽  
pp. S2 ◽  
Author(s):  
Carle Paul ◽  
Craig Leonardi ◽  
Alan Menter ◽  
Kristian Reich ◽  
Linda Stein Gold ◽  
...  
Keyword(s):  
Severe Psoriasis ◽  
Betamethasone Dipropionate ◽  
Post Hoc Analysis ◽  
Post Hoc

Abstract not available. Disclosures: Study sponsored by LEO Pharma. Copyright 2018 SKIN

scholarly journals Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis

2018 ◽  
Vol 79 (3) ◽  
pp. 593-595 ◽  
Author(s):  
Alice B. Gottlieb ◽  
Kim A. Papp ◽  
Charles A. Birbara ◽  
Catherine L. Shuler ◽  
Russel Burge ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Clinical Outcomes ◽  
Severe Psoriasis ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document